Signet Healthcare Partners provides growth capital to commercial stage healthcare companies around the world.
Chr Olesen Synthesis A/S (COS) a contract developer and manufacturer of technically complex active pharmaceutical ingredients (“APIs”). Based in Copenhagen Denmark, the Company operates a facility capable of producing both clinical and commercial-scale quantities. COS is presently using its technical expertise in producing complex and highly potent molecules for generic drug companies.
Headquartered in Munich, is a nanotechnology-based drug development company focused on reformulations and reinventions of drugs on a contract or co-development basis. The core business is the reformulations to develop novel oral and parenteral formulations and innovative drug combinations, which have not been possible in the past due to low bioavailability caused by low solubility of APIs.
A provider of technology-based products and services that enable the pharmaceutical, biotechnological, medical device, and contract resource companies to collect, interpret, and distribute cardiac safety and clinical data more efficiently.
A medical device company focused on improving surgery.
Medtronic is a medical device company that is committed to providing physicians with surgical tools that have the precision of a scalpel and the bleeding control of traditional electrosurgery without the extensive collateral damage – a revolutionary benefit that fills a critical market gap.
Develops, manufactures and markets a plasma based electrosurgical cutting tool.
Signet Healthcare partners was founded in 1998 with the establishment of the Corporate Opportunities Funds. Since 1998, we have organized three funds and completed investments in approximately 35 companies. The team is comprised of six professionals with principal offices in New York City. This team brings over 100 years experience of collective healthcare experience in the specialty pharmaceutical, medical device, private equity and investment banking businesses.
For the past sixteen years, Signet Healthcare has maintained its dedicated focus to diversified healthcare investing – primarily serving as lead investor to expansion stage companies engaged in specialty pharmaceuticals, medical devices and the pharma services industries.
We seek investment opportunities in which we can play an active and substantial role in helping management perform to their full potential and create shareholder value. We are both minority and majority investors in companies which are close to, or have achieved commercial operations and are seeking expansion stage capital. In general, we target investment opportunities where we can capitalize on operational efficiencies and revenue expansion opportunities through business development activities and product strategies, including life cycle management.
Innovation, access to technical skills, lower production costs, and sales and marketing opportunities have created opportunities outside the U.S. Since inception of our Funds, we have invested on a global basis with approximately 20% of our funds committed to entities domiciled in Europe and Asia. In general, we invest internationally with strong local investment partners.